Front Physiol (2019) 10:411
N Engl J Med 356:24572471 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-y ligand rosiglitazone
Book a free virtual consultation here: Call/Text: 312.312.7873 We offer personalized plans designed to support recovery, performance, and wellness goals safely and effectively
For this latest analysis, researchers explored real-world data from more than 90,000 HFpEF patients with obesity and type 2 diabetes who received treatment from 2018 to 2024
Women entering perimenopause at age 40-55 experience accelerated central adiposity despite unchanged caloric intake, driven by shifted estrogen-to-androgen ratios and impaired glucose-dependent insulin secretion